

# EATING DISORDERS

VLA 21. 3. 2017







# HISTORY

- <u>Lipostatic hypothesis</u> (Kennedy 1953) adipose tissue products specific "lipostatic" factor
- <u>Glukostatic hypothesis</u> (Mayer and Thomas 1967) – changes in glycemia lead to stimulation /inhibition of food intake (brain and liver)
- x Combination of both hypotheses???


#### IT IS NECESSARY TO DISTINGUISH COMMON HOMEOSTATIC REGULATIONS OF FOOD INTAKE AND HEDONIC REGULATIONS





SIMPLIFIED OF  $\subseteq$ )F SUBS. SIGNALS AL RI 7 ĸ Ð TIN, 22 ND ES А (INSULIN, ( -

#### CENTRAL AND PERIPHERAL CIRCUITS IN REGULATION OF FOOD INTAKE




Gut hormones and the regulation of energy homeostasis Kevin G. Murphy and Stephen R. Bloom Nature 444, 854-859(14 December 2006)

# PYY


- Peptide YY is related to the <u>pancreatic peptide</u> family by having 18 of its 36 amino acids located in the same positions as pancreatic peptide. The two major forms of peptide YY are PYY<sub>1-36</sub> and PYY<sub>3-36</sub>, which have PP fold structural motifs. However, the most common form of circulating PYY immunoreactivity is PYY<sub>3-36</sub>, which binds to the <u>Y2 receptor (Y2R)</u> of the <u>Y family</u> of receptors. Peptide YY<sub>3-36</sub> (PYY) is a linear polypeptide consisting of 36 <u>amino acids</u> with structural <u>homology</u> to <u>NPY</u> and <u>pancreatic polypeptide</u>.
- PYY is found in L cells in the <u>mucosa</u> of <u>gastrointestinal tract</u>, especially in <u>ileum</u> and <u>colon</u>. Also, a small amount of PYY, about 1-10%, is found in the <u>esophagus</u>, <u>stomach</u>, <u>duodenum</u> and <u>jejunum</u>. PYY concentration in the circulation increases postprandially (after food ingestion) and decreases by <u>fasting</u>. In addition, PYY is produced by a discrete population of neurons in the <u>brainstem</u>, specifically localized to the gigantocellular reticular nucleus of the <u>medulla oblongata</u>.
- \* PYY exerts its action through <u>NPY receptors</u>; it inhibits <u>gastric motility</u> and increases water and <u>electrolyte</u> absorption in the colon. PYY may also suppress <u>pancreatic</u> <u>secretion</u>. It is secreted by the <u>neuroendocrine cells</u> in the <u>ileum</u> and <u>colon</u> in response to a meal, and has been shown to reduce <u>appetite</u>. PYY works by slowing the gastric emptying; hence, it increases efficiency of digestion and nutrient absorption after a meal.

#### **REGULATION OF FOOD INTAKE**



Drug Insight: the functions of ghrelin and its potential as a multitherapeutic hormone Masayasu Kojima and Kenji Kangawa Nature Clinical Practice Endocrinology & Metabolism (2006) **2**, 80-88

# 1994 – ADIPOSE TISSUE IS ABLE TO PRODUCE HORMONS ITSELF – LEPTIN DISCOVERY




Mutation of *ob* gene coding for leptin is leading to significant obesity in mouse Leptin therapy led to normalized body weight and/or fertility of these mutated mice

Zhang et al, Nature, 1994.

### WAT produces adipokines

#### These factors are produced by adipocytes, but also by macrophages, fibroblasts, endothelial cells and other cells in adipose tissue


To date, a lot of adipose tissue-derived factors has been described. These factors with pleiotropic functions in many processes including regulation of energy metabolism, inflammation, food intake, insulin sensitivity etc. Markedly contribute to metabolic regulations and its pathologies.



They are usually:
1. Proinflammatory (TNF-α, IL-6, resistin)
2. Anti-inflammatory (adiponektin)


They are very important in metabolic regulations

In food intake and especially in postprandial supression of appetite, many substances produced in GIT play substantial roles.



Holst B, Schwartz TW. 2004

# OBESITY IS ASSOCIATED WITH LOCAL INFLAMMATORY RESPONSE IN FAT



#### PATHWAYS OF TRANSCRIPTION FACTORS PARTICIPATING IN NUTRITION BASED INTERACTIONS

Nutrient	Compound	Transcription factor					
Macronutrients							
Fats	Fatty acids Cholesterol	PPARs, SREBPs, LXR, HNF4, C SREBPs, LXRs, FXR	hREBP				
Carbohydrates	Glucose	USFs, SREBPs, ChREBP					
Proteins	Amino acids	C/EBPs					
Micronutrients							
Vitamins	Vitamin A Vitamin D Vitamin E	RAR, RXR VDR PXR					
Minerals	Calcium Iron Zinc	Calcineurin/NF-ATs IRP1, IRP2 MTF1	nature REVIEWS GENETICS				
Other food components							
	Flavonoids Xenobiotics	ER, NFĸƁ, AP1 CAR, PXR					

### SIZE AND ENDOCRINE PROFIL OF ADIPOCYTES IS CORRELATED WITH THE WHOLE ADIPOSITY










Malnutrition (Anorexia nervosa)

#### Normal state (slight overweight)) Obesity







# DIAGNOSTIC CRITERIA OF OBESITY (BMI)



 $BMI = \frac{Weight (kg)}{Height (m^2)}$ 

Classification	BMI (kg/m²)	metabolic rate
Normal body weight	18.5–24.9	average
Overweight	25–29.9	increased
Obesity I	30.0–34.9	middle
Obesity II	35.0–39.9	high
Obesity III	≥40.0	very high

WHO, 1998

# WAIST SIZE SEEMS TO BE THE BEST INDICATOR OF VISCERAL OBESITY



#### Women


>88 cm = highly increase risk<sup>1</sup>
>80 cm = higher risk<sup>1</sup>

#### Men

>102 cm = highly increased risk<sup>1</sup>
>94 cm = higher risk<sup>1</sup>

<sup>1</sup>Lean MEJ, et al. Lancet;1998:351:853-6

#### **STANDARDISED PREVALENCE OF OBESITY 2008**



on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. Data Source: World Health Organization Map Production: Public Health Information and Geographic Information Systems (GIS) World Health Organization



© WHO 2011. All rights reserved.


#### OBESITY

# Has obesity genetic background?

0	-	_	_	_	_		-	_	_	_	_	_	_	_	_
in Feel	5'8	18	20	21	23	24	26	27	29	30	3.2	34	35	37	38
Heighti	5'10	17	19	20	22	23	24	26	27	29	30	32	33	35	36
Hei	6'0	16	18	19	20	22	23	24	26	27	28	30	31	33	34
	6'2	15	17	18	19	21	22	23	24	26	27	28	30	31	32
	6'4	15	16	17	18	20	21	22	23	24	26	27	28	29	30
	6'6	14	15	16	17	19	20	21	22	23	24	25	27	28	29
	6'8	13	14	15	17	18	19	20	21	22	23	24	25	26	28
	Healthy Weight Overweight Obese														

#### **GENETICS OF OBESITY**

#### × Argumenst why yes:




#### **GENETICS OF OBESITY – ARGUMENTS WHY NOT**

#### IS OBESITY DONE BY CULTURAL EATING HABITS?



#### CLASSIFICATION OF OBESITY SYNDROMES



#### PLEIOTROPIC SYNDROMES WITH OBESITY

### About 30 syndromes, in which obesity represents constant component





### MONOGENIC SYNDROMES WITH OBESITY


Genes Implicated in Monogenic Obesity and the Traits Found To Be Associated with Them in Genome-Wide Association Studies (GWAS)

Gene symbol	Gene name	Phenotype	Associated traits			
BDNF	<i>NF</i> Brain-derived neurotrophic factor Wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity (WAGRO) syndrome		Obesity, BMI, weight			
CART	Cocaine- and amphetamine-regulated transcript	Severe obesity				
LEP	Leptin	Morbid obesity due to leptin deficiency				
LEPR	Leptin receptor	Severe obesity due to leptin receptor deficiency	Serum level of C-reactive protein, serum level of leptin receptor			
MC4R	Melanocortin-4 receptor	Early-onset severe obesity	Obesity, BMI, waist circumference, height, serum level of HDL cholesterol			
NTRK2	Neurotrophic tyrosine kinase, receptor, type 2	Early-onset severe obesity, hyperphagia, developmental delay				
PCSK1	Proprotein convertase subtilisin/kexin type Early-onset severe obesity 1 gene, or prohormone convertase 1		BMI, serum proinsulin level, fasting serum glucose level (interaction with BMI)			
РОМС	Proopiomelanocortin	Early-onset severe obesity, adrenal insufficiency, red hair	Obesity, height			
PPARG	Peroxisome proliferator-activated receptor gamma	Severe obesity, insulin resistance, lipodystrophy Type 2 diabetes, fasting insulin level (interaction BMI), plasma level of p activator inhibitor type				
SIM1	Single-minded homolog 1 (Drosophila)	Early-onset severe obesity, Prader-Willi syndrome				

Note. BMI, body mass index; HDL, high-density lipoprotein.

N C Med J. 2013; 74(6):530-533

# MONOGENIC OBESITY SYNDROMES



Prof.Stephen O'Rahilly, MD and I. Sadaf Farooqi, MD


Heiko Krude, Heike Biebermann, Werner Luck, Rüdiger Horn, Georg Brabant & Annette Grüters

# SY PRADER- WILLI AS A CLINICAL EXAMPLE

- Hypotonic children, mental retardation, small figure, behavioral complacations (hyperphagy as a result of incontrolled appetite – one of the most common causes of children obesity)
- Loss of expression of paternally imprinted genes at15q11.2-q13 chromosome as a result of microdeletion in the region.



#### OBESITY AS A COMMON (COMPLEX) DISEASE



# FUTURE

- **<u>BMC Med</u>**. 2017; 15: 50.
- Published online 2017 Mar 7. doi: <u>10.1186/s12916-017-0800-1</u>
- \* PMCID: PMC5340003
- \* Developmental pathways to adiposity begin before birth and are influenced by genotype, prenatal environment and epigenome
- Xinyi Lin,<sup>#1</sup> Ives Yubin Lim,<sup>#1,2</sup> Yonghui Wu,<sup>1</sup> Ai Ling Teh,<sup>1</sup> Li Chen,<sup>1</sup> Izzuddin M. Aris,<sup>1</sup> Shu E. Soh,<sup>1,3</sup> Mya Thway Tint,<sup>2,3</sup> Julia L. MacIsaac,<sup>4</sup> Alexander M. Morin,<sup>4</sup> Fabian Yap,<sup>5</sup> Kok Hian Tan,<sup>5</sup> Seang Mei Saw,<sup>6,7,8</sup> Michael S. Kobor,<sup>4</sup> Michael J. Meaney,<sup>1,9</sup> Keith M. Godfrey,<sup>10</sup> Yap Seng Chong,<sup>1,2</sup> Joanna D. Holbrook,<sup>1</sup> Yung Seng Lee,<sup>1,3,11</sup> Peter D. Gluckman,<sup>1,12</sup> Neerja Karnani,<sup>1,13</sup> and on behalf of the GUSTO study group

#### OBESITY AS A COMPLEX DISEASE

- Genetic, epigenetic and prenatal environmental factors are linked to offspring size and adiposity at birth and in early childhood.
- Individual prenatal environmental influences on birth weight was identified; some of these prenatal environment variables [maternal ppBMI, GWG ("Gestational Weight Gain") and glucose levels] continued to associate with offspring size and adiposity in early childhood.

# OBESITY AS A COMPLEX DISEASE


- Genetic variation, as captured by PRS ("Polygenic Risk Score"), not only influenced birth weight, but also child size and adiposity up to 48 months of age, independent of birth weight.
- \* The PRS was constructed using adiposity-linked genetic risk variants previously reported in an adult population. The association of adult adiposity risk score with size and adiposity in pediatric population indicates that the effects of genetic risk variants can be detected as early as birth.

#### OBESITY AS A COMPLEX DISEASE (BMC MED. 2017; 15: 50)


- Neonatal methylation levels at seven loci were associated with birth × weight. At six of the seven loci, there was suggestive evidence that the associations continued to persist up to 48 months of age. Among them, two of the loci (CDKN2B/P4HA3) also showed suggestive association with child BMI at 48 months. Even though the associations in early childhood did not survive multiple testing corrections, these CpGs still hold potential as biomarkers of adverse metabolic trajectory as the prevalence of obesity increases with age and might become more apparent later in the life-course. Lastly, methylation levels at three of seven loci associated with birth weight (IGDCC4, MIRLET7BHG, CACNA1G) also showed significant associations with the prenatal environment; however, similar analyses with childhood weight and adiposity measures showed suggestive associations.
- Birth weight seems to be influenced by both genetic and prenatal environment factors, possibly acting through different mechanisms, either by altering the epigenome (evidenced by CpGs that were associated with prenatal environment and/or SNPs) or independently of the epigenome (e.g. the PRS).

### ANOREXIA NERVOSA (AN) AND BULIMIA NERVOSA (BN)

- are complex psychiatric disorders of great importance for public health policies, as they are associated with a high burden of morbidity and mortality due to their severe medical and psychological consequences. Etiopathogenesis of these eating disorders (EDs) continues to remain elusive, with the result that their treatment is often unsuccessful.
- AN is a severe psychiatric disorder leading to life-threatening weight and fat loss. This illness could be characterized by irrational fear of becoming fat, abnormal eating behavior, hyperactivity, GIT complications and wide variety alterations of hormonal and metabolic systems.
- The exact etiopathogenesis is unknown and the way of treatment remain limited.







Schematic representation of brain reward circuits.

ACC anterior cingulated cortex; Amy amygdala; DS dorsal striatum; Hipp hippocampus; IC insular cortex; LH lateral hypothalamus; mPFC medial prefrontal cortex; NAc nucleus accumbens; OFC orbitofrontal cortex; VTA ventral tegmental area.

The brain reward system integrates basic and emotional stimuli, such as hunger, satiety, desire, pleasure and fear, with higher order cognitive processes aimed at modulating further actions or representation of the general experience. These high order processes involve anterior cingulate cortex (ACC), orbitofrontal cortex (OFC) and ventromedial prefrontal cortex (PFC), which are necessary for identification of rewarding stimuli, inhibition of emotional responses, and promote behavioral outcomes (Haber and Knutson, 2010; Wittman et al., 2010; Sripada et al., 2011). Overall, the PFC provides inhibitory influences on motivation and reward-directed behavior, integrating sensory inputs, memories, goals, and physiological states with the aim to provide an adequate performance (Miller and Cohen, 2001). ACC and dorsolateral prefrontal cortex (DLPFC) may also serve to monitor potential conflict situations induced by reward stimuli (Walton et al., 2003 ; Vogt et al., 2005). Therefore, they have a gating role in action selection following reward cues (Goldstein and Volkow, 2011). Indeed, by a top-down effect, both OFC and ACC provide a negative feedback to mesolimbic areas regulating reward-seeking motivation (Goldstein and Volkow, 2011).

# ANOREXIA NERVOSA (AN) AND BULIMIA NERVOSA (BN)

- \* Functional magnetic resonance imaging (fMRI) techniques have been employed to investigate the brain's processing of reward elicited by both food-related and non-food-related stimuli in AN and BN (<u>O'Hara et al., 2015</u>).
- It has been shown that, compared to healthy controls, AN patients exhibit abnormal activation of different brain areas, including the parietal, the orbito-frontal, the dorso-lateral prefrontal, the anterior cingulate and the medial prefrontal cortex (Frank, 2015a; Frank, 2015b) after exposure to visual food cues, especially for highly palatable foods. Similarly, altered insula, striatum or orbitofrontal responses to sweet stimuli have been found in recovered or symptomatic AN and BN patients. These findings suggest a dysregulation of brain mechanisms involved in the processing of food-related rewarding stimuli in the pathophysiology of EDs.

# ANOREXIA NERVOSA (AN) AND BULIMIA NERVOSA (BN)

- \* Compared to healthy women, symptomatic patients with AN and BN showed different patterns of brain area activation in response to pleasant and aversive basic taste stimuli with response activation by the pleasant sweet stimulus prevailing over that induced by the aversive bitter taste.
- \* Symptomatic AN patients showed a decreased response to the aversive bitter stimulus in the right amygdala and left anterior cingulate cortex while symptomatic BN individuals showed a reduced activation of right amygdala and left insula by the aversive bitter stimulus, which suggests an impairment of their physiological aversion to unpleasant bitter tastants. No quantitative differences emerged in brain responses to the pleasant sweet taste. These results may shed more light on the processing of rewarding and aversive food-related stimuli in patients with EDs, which may be relevant for understanding the pathophysiology of AN and BN.

#### LOSS OD ADIPOSE TISSUE IS SUPPOSED TO BE THE MAIN FACTOR CONTRIBUTING TO THE BODY WEIGHT LOSS

	NW (n = 50)	AN (n = 30)
Weight (kg)	62.2 ± 1.54	45.8 ± 1.89*
Lean mass (kg)	39.1 ± 0.76	37.8 ± 1.01
BMI (kg/m <sup>2</sup> )	21.2 ± 0.42	15.7 ± 0.47*
Body fat content (%)	24.3 ± 0.79	7.1 ± 0.88*
Total fat skinfold (mm)	120.5 ± 12.17	42.1 ± 4.78*
Abdominal skinfold (mm)	12.5 ± 2.13	4.8 ± 1.59*
Insulin (pmol/l)	28.3 ± 4.53	14.2 ± 3.67*
Glucose (mmol/l)	4.7 ± 0.08	4.1 ± 0.11
Menstruation	Yes - regular cycle	Secondary amenorrhea

### GENETIC ASSOCIATIONS???

- AN is 11x more frequent in relatives of probands compared to physiological population.
- BN is 4-5x more frequent in relative women.
- ~15% risk of eating disorders in relatives of AN and BN vs. 4% risk in healthy population.

Strober et al. Am J Psychiatry 2000; 157:393

# **DĚKUJI VÁM ZA POZORNOST**

